Merck’s $3 Billion Eye Disease Drug Meets Primary Endpoint in Phase 2b/3 Trial

Roche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027

BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors

Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”

CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count

Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash

MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882